E. Bayram

发表

Real-life comparison of afatinib and erlotinib in non-small cell lung cancer with rare EGFR exon 18 and exon 20 mutations: a Turkish Oncology Group (TOG) study

P. Gursoy, A. Erdoğan, A. Bilici, 2021, Journal of Cancer Research and Clinical Oncology.

Pretreatment neutrophil-to-lymphocyte ratio and Mean Platelet Volume in castration-resistant prostate cancer patients treated with first-line docetaxel

T. Çil, B. Yıldız, M. Dinçer, 2019 .

Is the benefit of using adjuvant capecitabine in patients with residual triple-negative breast cancer related to pathological response to neoadjuvant chemotherapy?

Erkan Özcan, M. Gümüş, O. Selvi, 2022, Expert review of anticancer therapy.

Sleep Quality Analysis in Metastatic Breast Cancer Patients Receiving Cyclin-Dependent Kinase 4-6 Inhibitor

T. Şakalar, S. Ay, Ö. Dülgar, 2022, Journal of Oncological Sciences.

Turgay Demir, S. Bicakci, E. Bayram, 2022, Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners.

Prognostic importance of peripheral blood parameters in HER-2 positive metastatic breast cancer treated by pertuzumab, trastuzumab and docetaxel

T. Çil, S. Ata, M. Sungur, 2021, Medical Science and Discovery.

Developments with 3D bioprinting for novel drug discovery

Ibrahim T. Ozbolat, Pallab Datta, Yang Wu, 2018, Expert opinion on drug discovery.

Real-world data on efficacy and safety of first-line alectinib treatment in advanced-stage, ALK-positive non-small-cell lung cancer patients: a Turkish Oncology Group study.

D. Erdem, B. Öksüzoğlu, D. Aydın, 2022, Future oncology.

Treatment efficacy of ribociclib or palbociclib plus letrozole in hormone receptor-positive/HER2-negative metastatic breast cancer.

U. Demirci, Ozlem Dogan, A. Erdoğan, 2023, Future oncology.

Investigation of the change in the biological structure of the tumor in metastatic breast cancer

T. Çil, B. Duman, P. Olgun, 2021 .

The percentage of ALK-positive cells and the efficacy of first-line alectinib in advanced non-small cell lung cancer: is it a novel factor for stratification? (Turkish Oncology Group Study)

D. Erdem, D. Aydın, B. Yalcin, 2022, Journal of Cancer Research and Clinical Oncology.

Refractory idiopathic multicentric Castleman disease responsive to sirolimus therapy

D. Fajgenbaum, S. Paydaş, E. Bayram, 2022, American journal of hematology.

Neutrophil-to-lymphocyte ratio is prognostic in recurrent glioblastoma multiforme treated with bevacizumab plus irinotecan.

E. Topkan, P. Olgun, E. Bayram, 2021, Biomarkers in medicine.

The percentage of ALK-positive cells and the efficacy of first-line alectinib in advanced non-small cell lung cancer: is it a novel factor for stratification? (Turkish Oncology Group Study)

D. Erdem, D. Aydın, B. Yalcin, 2022, Journal of Cancer Research and Clinical Oncology.

Efficacy of subsequent treatments in patients with hormone-positive advanced breast cancer who had disease progression under CDK 4/6 inhibitor therapy

Ö. Acar, A. Erdoğan, Kubilay Karaboyun, 2023, BMC Cancer.

Severe Lymphocytosis in a Case of Diffuse Large B-Cell Lymphoma Treated by Ibrutinib

S. Paydaş, M. Türker, E. Bayram, 2021, Turkish journal of haematology : official journal of Turkish Society of Haematology.

Comparison of different cyclin-dependent kinase inhibitors and KI-67 levels on survival and toxicity in breast cancer treatment.

S. Paydaş, O. Selvi, E. Bayram, 2023, European review for medical and pharmacological sciences.

Pretreatment Modified Glasgow Prognostic Score for Predicting Prognosis and Survival in Elderly Patients with Gastric Cancer Treated with Perioperative FLOT

Şaban Seçmeler, E. Bayram, Ebru Melekoğlu, 2023, Nutrients.